Vium Explores Automated In Vivo Efficacy Assessment in Educational Webinar
YORBA LINDA, Calif. (PRWEB) June 06, 2018 -- Treatments for respiratory diseases represent an enormous, unmet medical need with limited therapies currently approved for use. Despite many compounds demonstrating beneficial effects in animals models, very few translate into successful therapies.
To improve translational efficacy of respiratory animal models, researchers are calling for the development of new druggable targets, better biomarkers and the use of more clinically relevant endpoints in preclinical animal studies.
This presentation will describe a novel technology platform that allows for non-invasive real-time monitoring of lung function in preclinical studies of respiratory disease and will present several use cases demonstrating how automated longitudinal monitoring provides insight into disease biology in animal models of Idiopathic Pulmonary Fibrosis (IPF) and Pneumonia.
The speaker for this event will be Dr. Laura Schaevitz, vice president of scientific technologies at Vium.
As an industry veteran with more than 15 years of experience with In vivo animal studies, Schaevitz oversees the development of animal models and draws upon her experiences as a molecular and behavioral neuroscientist to direct the application of Vium's digital metrics to the animal models. She has utilized a broad spectrum of mouse models including transgenic and nutrition-induced models of neurodevelopmental disorders.
In this webinar, which is sponsored by Vium, Schaevitz will review methods and best practices for automated collection of breathing data and comparison of data collection to traditional techniques.
LabRoots will host the webinar June 26, 2018, beginning at 9 a.m. PDT, 12 p.m. EDT. To learn more about this event, discover the continuing education credits offered, or to register for free, click here.
About Vium, Inc.
Vium has developed the world’s first Digital Vivarium®, a fully integrated hardware and software platform for preclinical in vivo drug research and development that operates at scale. The platform, incorporating Vium Smart Housing™, Vium Cloud infrastructure, and Research Suite software, empowers scientists to optimize in vivo disease research and advance drug development. Vium is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the ”3 Rs,” the gold-standard framework for humane animal research. Customers include pharmaceutical, biotechnology and computational drug discovery companies, academia and health science research centers. Vium is backed by leading investors, including Lux Capital, Data Collective, Dolby Family Ventures, AME Cloud Ventures, and Founders Fund.
Vium is headquartered in San Mateo, California. For more information, please visit http://www.vium.com.
About LabRoots
LabRoots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. We have become a primary source for trending scientific news, webinars, virtual conferences and more. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Join for free and become part of the largest scientific learning community in the world.
Karen Sorenson, LabRoots, Inc., http://www.LabRoots.com, +1 (619) 861-0590, [email protected]
Share this article